Why Insiders Are Buying This Biotech Stock 🧬

Up 170% this year, and more to go?                                                                                                                                                                                                                                                                                                                                                                                                                 November 07, 2024 | [Read Online]( Why Insiders Are Buying This Biotech Stock 🧬 *Sponsored by Sica Media TODAY’S TOP ALERT! Nasdaq: MAIA Good morning! As though yesterday’s incredible post-election rally wasn’t enough, stock futures are green again today ahead of Powell’s press conference this afternoon. The Wall Street Journal is [reporting]( that “Wall Street Salivates Over a New Trump Boom.” One line that jumped out at me: “Nowhere was the economic optimism more apparent than in small-cap stocks.” That’s music to my ears! As you know, I love small-cap “tactical trade” ideas, and I’ve been on a multi-week win streak alerting one after the next. My most recent idea from Monday spiked as high as 40% before closing the day up more than 15%. Can I do it again? Let’s find out. Today’s “tactical” idea is…  MAIA Biotechnology, Inc. (MAIA) I first brought this stock to readers’ attention last year, and I hope they listened because the stock has been on a rampage since January, outpacing the SPY by nearly 600%! In the last few weeks alone, the stock broke past major resistance to climb 30%... And it’s showing no signs of stopping. Yesterday, there was a nearly 4% jump, and it is up again this morning in pre-market trading. This stock is critical to watch right now because, as I’ll explain, there were some huge stock purchases by insiders in the past week, and the company has telegraphed that it’s likely dropping big news tomorrow. Of course, it’s best to get in front of good news, which is why you must watch MAIA today. Here are some details about the company itself… MAIA is a clinical-stage biopharmaceutical company exploring genuinely groundbreaking cancer treatments. Its lead asset — called THIO — “is the only direct telomere targeting agent currently in clinical development.” Its action in cancer treatment has been featured in renowned publications such as Cancer Cell and Nature. Here’s how it works… There’s an enzyme called telomerase that’s present in 85% to 90% of human cancers and that “contributes significantly to the proliferation and reproductive immortality of cancer cells.” According to the company, “THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death.” On top of killing the cancer cells directly, THIO — coupled with an [immune checkpoint inhibitor]( — seems to produce an immune memory specific to cancer cells “where the immune system [continues] to be active against the cancer cells after extended periods of time, with no additional treatment.” If you know anything about cancer, you know that maintaining remission is the truly critical part of therapy, and THIO is showing promise in that respect. On February 22, MAIA [announced]( the completed enrollment of its Phase 2 clinical trial for THIO in cases of non-small cell lung cancer (NSCLC), noting that “preliminary data has demonstrated unprecedented rates of disease control and response to date.” And on June 4, the company [revealed]( new data on the trial, including a favorable overall response rate of 38% and a disease control rate of 85%. MAIA CEO Vlad Vitoc said, “All exceptional measures of efficacy in our trial to date have exceeded our own expectations and outperformed standard of care treatments.” He added that the data “advances THIO’s excellent clinical profile as a strong, safe, and highly effective alternative for patients who progressed following chemotherapy and other available treatments.” A July update [noted]( that “Treatment with THIO followed by cemiplimab has been well tolerated throughout the trial, with much lower toxicity compared to standard-of care treatments.” As of September, the company [says]( the Phase 2 trial is “nearing completion” and that it expects long-term data before the new year. And just on Tuesday, MAIA [announced]( it will be detailing new updates from the trial in an oral and poster presentation at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer… The presentation takes place very soon and the poster will be made available [on this page]( at that time. Folks, biotech companies don’t present new data at prestigious conferences unless the data are impressive. I take this as a great sign and it could lead to big price action in the stock tomorrow. MAIA notes that NSCLC is “the largest tumor type globally by mortality (1.7 million deaths annually) and dollar sales ($34 billion annually).” But it appears that THIO may prove effective well beyond NSCLC… For instance, it has been granted three [Orphan Drug Designations]( (ODD) by the FDA for “hepatocellular carcinoma (the dominant histology of primary liver cancers, ~90%), small cell lung cancer (the deadliest type of lung cancer), and malignant gliomas (the deadliest group of brain cancers, including glioblastomas).” These designations afford the company seven years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing. In upcoming clinical trials, MAIA will be pitting THIO against the likes of small-cell lung cancer, liver cancer, and colorectal cancer. On top of all this, MAIA is developing a second generation of THIO-derived drugs. They’ve advanced more than 80 to date, with three U.S. patent applications. According to the company, “Preclinical studies of several of these agents have shown highly significant anti-cancer efficacy at low dose levels in multiple in vivo and in vitro models.” For a more detailed breakdown of MAIA’s trial progress and drug pipeline, check out [this press release]( that the company put out on June 6 detailing year-to-date progress. Company insiders have been scooping up MAIA shares hand over fist over the past week, with director Stan Smith [purchasing]( $250k worth, director Steven Chaouki [buying]( $55k worth, and director Ramiro Guerrero [grabbing]( $222k worth. Do you think they may be front-running some excellent news? Reminder: The company has a big presentation that includes new data dropping tomorrow. Beyond that, in September, Noble Financial reiterated a $14.00 12-month price target on the stock, marking a 340% increase from its current price, as you can see [from this chart](: Folks, you need to do your homework on MAIA immediately, beginning with the [company website]( and [this investor presentation](. As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration. Bottom line: MAIA has rocketed 171% YTD and 30% in the last few weeks alone. Company insiders bought tons of shares in the past week, and the company telegraphed that important new data will be dropping tomorrow. You need to get MAIA on the top of your radar today in advance of the big news drop tomorrow. To Your Success, Jeff Bishop P.S.Don't miss out on our MOBILE ALERTS! We have seen some of these alerts rocket 🚀past the MOON 🌝. To be first in line for the next one, simply text the word “RAGE” to 1-(888) 404-5747 📲.  Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull  *Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.” Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we currently have received twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on November 7, 2024. Previously, we received twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on July 9, 2024 and also fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 13, 2024. Previously, we received twelve thousand five hundred dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 7, 2024. Also, we were paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc for a one day marketing program on March 6, 2024. We were also previously paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15 through November 18, 2023, and also fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. These amounts were paid by someone else not connected to MAIA Biotechnology, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. Now, diving right into MAIA Biotechnology, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now. Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. [tw]( Update your email preferences or unsubscribe [here]( © 2024 Bullseye Trades 62 Calef Hwy. #233 Lee, NH 03861, United States of America [Terms of Service](